Catalyst Pharmaceuticals Earns Zacks Rank #1 with 35.2% Earnings Surprise
Catalyst Pharmaceuticals earned a Zacks Rank #1 designation after raising its current-year earnings estimate to $2.82 per share and delivering an average earnings surprise of 35.2% over the past four quarters. Analysts project 7% revenue growth to $630.3 million for the year.
1. Zacks Rank Achievement
Catalyst Pharmaceuticals was awarded a Zacks Rank #1 rating after analysts raised its current-year earnings estimate by $0.35 to $2.82 per share, reflecting strong earnings momentum and fundamental strength.
2. Earnings Surprise Trend
The company has exceeded analyst forecasts in each of the last four quarters, delivering an average earnings surprise of 35.2%, underscoring consistent outperformance.
3. Revenue Growth Outlook
The Zacks consensus projects current-year revenues of $630.3 million, representing a 7% increase year over year and highlighting steady top-line expansion.